However, caution must be exerted even if pivotal studies do not report an increased infectious risk. Indeed, in the past, most of the data on particular, and usually quite rare, infectious complications occurring during treatment with novel agents have been discovered only after ACCEPTED MANUSCRIPT 5 extensive post-marketing use, and reported either as case series or data from large observational studies.
The development status, therapeutic indications and the potential impact on the infectious risk of the reviewed agents are summarized in Table 1 . The available data on infectious complications extracted from studies that included a control group are outlined in Table 2 Finally agents data a for con particu promp rare bu
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The an or higher within 4 weeks from the initiation of therapy, with B-cell recovery occurring at 9 to 12 months after the last infusion. Serum immunoglobulin levels were measured before, during and 7 after drug exposure, and no significant decrease was documented [11, 12] . In SLE patients a median reduction of 30-40% in peripheral blood B-cell levels was observed, although T-cell and serum IgA and IgG levels remained stable throughout therapy, whereas IgM levels decreased by 20% from baseline among epratuzumab-treated patients [6] . • Anti-herpesvirus and anti-Pneumocystis prophylaxis should be administered to autologous
• PML is a life-threatening complication occasionally associated with the use of brentuximab 
Expected impact on the infection risk
CD33 is expressed on monocytes, granulocytes, mast cells and myeloid progenitors. Due to the cytotoxic effect exerted on immature myeloid cells, CD33-targeted therapy leads to profound neutropenia and thrombocytopenia. The expected impact of gemtuzumab ozogamicin on the incidence of infection would be thus similar to that observed with other therapies inducing severe and long-lasting neutropenia (e.g., induction to remission cytotoxic therapies for AML). The rate of varicella zoster virus (VZV) infection in the daratumumab arms of the pivotal studies for relapsed/refractory myeloma ranged from 2% to 5% [42, 43] . This finding is likely explained by the inclusion of immunomodulatory agents, proteasome inhibitors and corticosteroids within the combination regimens evaluated in these trials. In addition, it should be noted that the rate of infection among myeloma patients is higher for relapsed/refractory cases and those with
Available clinical data
Result
Isatuximab is another potent anti-CD38 monoclonal antibody, and several phase 2 studies are ongoing to evaluate its role in heavily pre treated myeloma patients Pneumonia and sepsis The most frequent adverse event reported in patients treated with elotuzumab is lymphopenia.
CD319-targeted agents: elotuzumab
Mechanism of action, approved indications and off-label uses
Since elotuzumab is mainly used in combination with other anti-myeloma drugs, it is difficult to discern if the observed infections may be directly attributable to the effect of elotuzumab. The expected impact would be similar to that associated to usual anti-myeloma drugs, such as protease inhibitors, lenalidomide or dexamethasone. 
Available clinical data
CCR4-targeted agents: mogamulizumab
Mechanism of action, approved indications and off-label uses
Mogamulizumab (Poteligeo ® , Kyowa Hakko Kirin) is a recombinant humanized IgG1 monoclonal antibody that targets CC chemokine receptor 4 (CCR4) and depletes CCR4
Available clinical data
Four phase 2 trials found no significant differences in the incidence of infections between study groups. In the first single-arm trial in 27 patients with relapsed ATLL, no data on infections were 
